Genmab (GMAB) Fuels Confidence Based on Upcoming Epkinly and Petosemtamab Readouts

Genmab A/S (NASDAQ:GMAB) is one of the 15 large cap stocks under $30 with huge upside potential.

As of the March 23 closing, consensus sentiment for Genmab A/S (NASDAQ:GMAB) remained strongly bullish. The stock received coverage from 9 analysts, 7 of whom assigned Buy ratings and 2 gave Hold calls. With no Sell rating, it has a projected median 1-year price target of $39.25, resulting in an upside potential of almost 53% at the prevailing level.

Billion Photos/Shutterstock.com

On March 2, Wells Fargo began coverage of Genmab A/S (NASDAQ:GMAB). The firm assigned an Overweight rating to the stock, with a target price of $40. This results in an upside potential of almost 56% at the current level.

Based on Phase 2 data, the firm highlighted that the company’s impending Epkinly and petosemtamab readouts are substantially de-risked. Furthermore, Genmab A/S (NASDAQ:GMAB) shares at current levels do not represent petosemtamab’s potential outside head and neck cancer. According to Wells Fargo, 2026 will be a pivotal year for the company due to several factors.

Back on February 23, Genmab A/S (NASDAQ:GMAB) was subject to a target price reduction by Guggenheim analyst Michael Schmidt. The analyst lowered the firm’s target from $45 to $40, while reiterating his Buy rating on the stock. Schmidt attributed this downward revision to a deflated outlook for Epkinly, in the near term.

Genmab A/S (NASDAQ:GMAB) is a biotechnology company based in Denmark that develops antibodies and related products to treat cancer and other diseases. The company markets various cures for adults, including EPKINLY, TEPKINLY, and Tivdak.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.